Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with very low- to intermediate-risk MDS with ring sideroblasts or MDS/MPN with ring sideroblasts and thrombocytosis, whose anemia did not respond to an erythropoiesis-stimulating agent and required at least two red-cell units over eight weeks.
LAMPGEN ANALYSIS
Why it matters
Added an anemia treatment for a defined group with ongoing transfusion requirements.
What research teams should watch
Verify ring sideroblast classification and reconcile the rolling red-cell transfusion record before eligibility review.
PRIMARY RECORDS